AI Terminal
ABIVAX
Report Publication Announcement • Sep 30, 2022
1063_rns_2022-09-30_bab8bed3-1f9c-4d04-9784-835939eb7d01.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
News Details
Corporate | 30 September 2022 18:00
ABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORT
EQS-News: ABIVAX / Key word(s): Half Year Results
ABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORT
30.09.2022 / 18:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
ABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORT
PARIS, France, September 30, 2022 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces the publication of its 2022 half-year financial report.
This document is available in electronic version on the website of the company ( www.abivax.com – “Investors” ) and on the website of the French financial markets authority, AMF ( www.amf-france.org ).
*****
About Abivax ( www.abivax.com )
Abivax, a phase 3 clinical stage biotechnology company, is developing novel therapies that modulate the body’s natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, obefazimod (ABX464) to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com . Follow us on Twitter @ABIVAX_.
Contacts
| Abivax Communications Regina Jehle [email protected] +33 6 24 50 69 63 |
Investors LifeSci Advisors Ligia Vela-Reid [email protected] +44 7413 825310 |
Press Relations & Investors Europe MC Services AG Anne Hennecke [email protected] +49 211 529 252 22 |
| Public Relations France Actifin Ghislaine Gasparetto [email protected] +33 6 21 10 49 24 |
Public Relations France Primatice Thomas Roborel de Climens [email protected] +33 6 78 12 97 95 |
Public Relations USA Rooney Partners LLC Jeanene Timberlake [email protected] +1 646 770 8858 |
30.09.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com